Sevoflurane – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:08 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Sevoflurane – CRI Report https://www.cri-report.com 32 32 Investigation Report on Chinese Sevoflurane Market, 2021-2025 https://www.cri-report.com/investigation-report-on-chinese-sevoflurane-market-2021-2025/ Sat, 10 Apr 2021 06:25:37 +0000 https://www.cri-report.com/?post_type=product&p=10974 According to CRI's market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019. The CAGR for Sevoflurane from 2016 to 2019 is about 2.41%.

The post Investigation Report on Chinese Sevoflurane Market, 2021-2025 first appeared on CRI Report.

]]> Sevoflurane is an inhalation general anesthetic and also the main inhalation anesthetic at this stage. Inhaled Sevoflurane was originally developed by Abbott and entered the Chinese market in 1996.

In the Chinese market, with the prevalence of chronic diseases, the improvement of the medical system, and the intensification of aging in some regions, the number of operations has increased. Moreover, due to the therapeutic advantages of Sevoflurane, it dominates the anesthesia market. Therefore, CRI predicts that the sales of Sevoflurane will increase in the future.

According to CRI’s market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019. The CAGR for Sevoflurane from 2016 to 2019 is about 2.41%. In 2020, due to the COVID-19 epidemic, the number of surgeries decreased. Thus, the sales of Sevoflurane decreased accordingly. However, CRI analyzes that as the epidemic has improved, the sales of Sevoflurane in the Chinese market will have a recovery growth in 2021-2025.

Topics Covered:
-The impact of COVID-19 on China’s sevoflurane market
– Sales value and volume of China’s sevoflurane 2016-2020
– Competitive landscape of China’s sevoflurane market
– Prices of sevoflurane in China
– Prices of sevoflurane in China by regions and manufacturers
– Analysis on factors affecting the development of China’s sevoflurane market
– Prospect of China’s sevoflurane market from 2021 to 2025

The post Investigation Report on Chinese Sevoflurane Market, 2021-2025 first appeared on CRI Report.

]]> Investigation Report on Sevoflurane in China, 2020-2024 https://www.cri-report.com/investigation-report-on-sevoflurane-in-china-2020-2024/ Tue, 20 Oct 2020 02:29:44 +0000 https://www.cri-report.com/product/import-placeholder-for-2010440/ Description Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage. According to CRI’s analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter…

The post Investigation Report on Sevoflurane in China, 2020-2024 first appeared on CRI Report.

]]> Description
Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.
According to CRI’s analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, Chinese government approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.
As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 266 million in 2019, with the CAGR up to 7.9%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.
According to CRI’s research, sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 723.4 million in 2019 and the CAGR is about 19.8% in 2007 to 2019.
According to CRI’s market research, the major market share holders in China are Shanghai Hengrui Pharmaceutical Co., Ltd., Maruishi, Baxter and Lunan Better Pharmaceutical Co., Ltd. In terms of sales value, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which was about 66.4% in 2019.
According to CRI’s market research, in 2020, due to the COVID-19 epidemic, the number of surgeries in Chinese hospitals will decrease, so the sales of sevoflurane will also decrease accordingly. It is expected that from 2021 to 2024, the demand for sevoflurane in the Chinese market will show a recovery growth.

Topics Covered:
-Indication of sevoflurane
-Sales volume and value of sevoflurane in China 2015-2019
-Sales volume and value of sevoflurane in different regions of China 2015-2019
-Major sevoflurane manufacturers in the Chinese market
-Competition pattern of sevoflurane in China
-Sale price of sevoflurane in China
-Sale price of sevoflurane by manufacturers and regions in China
-Prospects of sevoflurane in China 2020-2024
-The impact of the COVID-19 outbreak on China’s sevoflurane market

The post Investigation Report on Sevoflurane in China, 2020-2024 first appeared on CRI Report.

]]> Sample of Investigation Report on Sevoflurane in China, 2018-2022 https://www.cri-report.com/sample-of-investigation-report-on-sevoflurane-in-china-2018-2022/ Thu, 03 Jan 2019 09:14:42 +0000 https://www.cri-report.com/?post_type=product&p=6736 This is a free sample of Investigation Report on Sevoflurane in China, 2018-2022

The post Sample of Investigation Report on Sevoflurane in China, 2018-2022 first appeared on CRI Report.

]]> This is a free sample of

Investigation Report on Sevoflurane in China, 2018-2022

The post Sample of Investigation Report on Sevoflurane in China, 2018-2022 first appeared on CRI Report.

]]> Investigation Report on Sevoflurane in China, 2018-2022 https://www.cri-report.com/investigation-report-on-sevoflurane-in-china-2018-2022/ Fri, 17 Aug 2018 09:05:11 +0000 https://www.cri-report.com/product/import-placeholder-for-1806292/ CRI market research shows that sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 633 million in 2017.

The post Investigation Report on Sevoflurane in China, 2018-2022 first appeared on CRI Report.

]]> Description
Sevoflurane is an inhaled general anesthetic featured with rapid induction and quick wake-up of patients. It has slight inhibition on circulation, little effect on liver and kidney function and a clear myocardial protective effect. Therefore, sevoflurane has now become the main inhaled anesthetic and is particularly suitable for patients with myocardial damage.
According to CRI’s analysis, in 1996, the sevoflurane of Abbott entered the Chinese market, but currently Abbott holds a very small market share. The approved imported sevoflurane also comes from Maruishi and MARUKO of Japan and Baxter of the United States. In 2007 and 2008, CFDA approved the inhaled solution sevoflurane of Shanghai Hengrui Pharmaceuticals and Lunan Better Pharmaceutical to go public in China. Gradually, domestic sevoflurane dominates the Chinese market.
As the environmental pollution intensifies and the population ages, the demand for medical services is rapidly rising. The hospitalization increased from 115 million in 2008 to 227 million in 2016, with the CAGR up to 7.8%. Among them, one quarter of patients was hospitalized for surgery. The increasing amount of surgery boosts the demand for narcotic drugs.
CRI market research shows that sales value of sevoflurane in the Chinese market rose from less than CNY 4 million in 2005 to CNY 82.8 million in 2007 and to CNY 633 million in 2017. The CAGR during 2007 to 2017 reached about 22.6%.
According to CRI’s market research, the major market share holders in China are Maruishi, Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd., Baxter, MARUKO and Lunan Better Pharmaceutical Co., Ltd. In terms of sales volume, Shanghai Hengrui Pharmaceutical holds the biggest market occupancy, which in 2017 was about 55%.
It is expected that with the increasing surgery in China from 2018 to 2022, the demand for narcotic drugs will continue to increase, creating a promising future market for sevoflurane.

Topics Covered:
Indication of sevoflurane
Market size of sevoflurane
Major sevoflurane manufacturers in the Chinese market
Competition pattern of sevoflurane in China
Sale price of sevoflurane in China
Prospects of sevoflurane

 

The post Investigation Report on Sevoflurane in China, 2018-2022 first appeared on CRI Report.

]]>